Sciele Pharma, Inc., a Shionogi troop, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of stock for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency span (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory limitation and Sexual Satisfaction domains), but as well all secondary endpoints.

The paying European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The lower Phase III study is expected to be completed in the first half of 2009. dope from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients crosswise the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients crosswise 32 investigational centers in four countries crosswise Europe. Of these, 268 patients have now hasantique entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant incorporation from baseline in all three coprimary study endpoints, but as well in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p

The Everett Herald that week published a fourshare series in correct Received Standard and Spanish examining mental hardiness issues among Hispanics living in Washington state. The series is a atom of a salubrity journalism program offered through the AnnenbergCalifornia Endowment verdure Journalism Fellowships, administered by the University of Southern California Annenberg School for Communication. Headlines of the series appear below.”Alone Among Us” (Sayler/Dominguez, Everett Herald, 12/7).

“Fear of Loco Label” (Sayler/Dominguez, Everett Herald, 12/8).

“Cultures gyre to Traditional Ways to Heal” (Sayler/Dominguez, Everett Herald, 12/9).

“Mental Illness Carries Stigma Among Asian Cultures, Too” (Sayler/Dominguez, Everett Herald, 12/9).
Reprinted with kind permission from kaisernetwork.org. You can view the entire Kaiser Daily tonicity method Report, search the archives, or warning up for letter delivery at kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily tonicity order Report is published for kaisernetwork.org, a free advantage of The Henry J. Kaiser pedigree Foundation.

&counterpart; 2008 Advisory Board horde and Kaiser birth Foundation. All rights ceremonious.

AstraZeneca is petitionsed to see additional info presented at SABCS reinforce that there is no evidence that a sequencing strategy is superior to a 5 year aromatase inhibitor (AIs) strategy.

AstraZeneca believes that AIs should be used upfront in all newly diagnosed breast cancer postmenopausal women as it is critical to keep patients cancer free for as continued as promising.

Anastrozole (Arimidex)Anastrozole ( Arimidex), which is used to treat women with postmenopausal breast cancer, has the largest comprehensive clinical evidence of any AIs in preventing recurrence in postmenopausal women with hormone receptorpositive (HR+ve) early breast cancer immediately following surgery.

In women with hormone receptor positive breast cancer, after a median followup of bygone 8.3 years (100 months), compared with tamoxifen, anastrozole significantly Improves span to recurrence (HR 0.76 [0.670.87]; p=0.0001).

improves disease free survival by 15% (HR 0.85 [0.760.94]; p=0.003).
improves future to distant recurrence (recurrence elsewhere in the body) by 16% (HR 0.84 [0.720.97]; p=0.022).
reduces the incidence of contralateral breast cancer (cancer in the opposite breast) by 40% (HR 0.60 [0.420.85]; p=0.004).

AstraZeneca is committed to improving lives of women with breast cancer.

1. Letrozole following breast cancer surgery may provide survival benefit. Abstract #13, Alan Coates, M.D. Embargo 945 a.m. CST, December 11, 2008. Letrozole may improve overall survival in patients with primary breast cancer. A fourarm comparison study of letrozole and tamoxifen shows letrozole not only reduces recurrence, but may provide a 13 percent reduction in risk of curtains. Additionally, the study finds that using a sequence of tamoxifen and letrozole is not superior to letrozole alone. The sequence of letrozole followed by tamoxifen was closely similar to letrozole alone implying that patients can safely switch to tamoxifen after initial letrozole if imperious.

2. SmPc. medicines.org.uk/

3. The ATAC Trialists Group Effect of anastrozole and tamoxifen as adjuvant treatment for earlystage breast cancer; 100 month analysis of the ATAC trial. The Lancet Oncology, 2008; 9 (1) 4553.

Sciele Pharma, Inc., a Shionogi ring, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of commodities for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency instance (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory weight and Sexual Satisfaction domains), but likewise all secondary endpoints.

The fruitful European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The subsequent Phase III study is expected to be completed in the first half of 2009. circumstances from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients over the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients crossed 32 investigational centers in four countries transversely Europe. Of these, 268 patients have now obsolete entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant incorporation from baseline in all three coprimary study endpoints, but wellorganized with in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p

Research by a Michigan State University chemist could eventually priority to a quicker and easier way of developing proteinbased drugs that are key to treating a total of diseases, including cancer, diabetes and hepatitis.

Proteins used in drug manufacture and research recurrently are made within genetically modified Escherichia coli, a onecell bacteria. That protein tends to collect into what scientists yawp inclusion bodies. Those hardtoseparate clumps render up to 95 percent of the protein unusable, according to associate chemistry professor David P. Weliky.

Some can be recovered by breaking down the protein to separate it, but owing to protein structure determines its business, another step must be added to “refold” it into its original configuration.

Weliky and colleagues took a closer look at the structure of the proteins that whip out up these inclusion bodies. Learning what initiates them stick stable might yield some clues as to how to separate them, he said, and that could compose the manufacturing process more efficient.

Instead of employing more commonly used infrared spectroscopy to look at dehydrated samples, the researchers used nuclear magnetic resonance spectroscopy using whole cells. That technology analyzes the magnetic properties of an atoms nucleus.

While beyond compare known as medical diagnostic imaging technology, Weliky and colleagues view NMR as a authoritative approach to analyzing biological molecules, including bacterial inclusion bodies. being the inclusion body protein occured to be predominantly folded rather than unfolded, it might be on to extract protein outwardly separating and anew refolding, Weliky said.

“that study highlights our ability to probe the molecular structure of a isolated protein in whole cells and to apply excellent analytical and biochemical rubrics to a problem of general significance in biotechnology,” Weliky said.

beat adapted by Medical News Today from original press release.

that research by Weliky and students Jaime CurtisFisk and Ryan M. Spencer was latterly featured in Chemical and Engineering News, the membership publication of the American Chemical Society.

Proteins are pivotal biological macromolecules, forming enzymes critical for metabolism, giving cells structural support and comprising key parts of cell signaling, immune response and other life activities. In other words, whatever happens within a living organism, proteins probably cook it pass or regulate it.

The creation protein therapeutics mart totaled $63 billion in 2007, according to warehouse research firm Kalorama ammo, and could reach $87 billion by 2010. It mints to some $39 billion in the United States alone, propelled by recombinant insulin and other drugs. As protein drug use has increased, so has the craze for manufacturing capacity and ways to streamline the production of protein.

To access the commentary in Chemical and Engineering News, surf the Web at pubs.acs.org/isubscribe/journals/cen/86/i41/html/8641sci1.html. For the original research paper, published in the Journal of the American Chemical Society, go to pubs.acs.org/doi/full/10.1021/ja8039426.

For additional whats what on Welikys research group, browse chemistry.msu.edu/Faculty/Welikygrp/index.html.

Michigan State University has obsolescent advancing knowledge and transforming lives through innovative teaching, research and outreach for more than 150 years. MSU is known internationally as a major public university with global reach and extraordinary impact. Its 17 standardgranting colleges attract scholars worldwide who are interested in combining indoctrination with practical problem solving.

Source Mark Fellows
Michigan State University

In recent conflicts, largest notably in Rwanda, women and girls have olden systematically raped as a plan of war. as the Rwandan Genocide of 1994, Hutu leaders ordered their troops to rape Tutsi women as module of their genocidal drive. United Nations officials estimated that a quarter of a million women were raped and subjected to sexual violence on a massive scale. A new study published in the Journal of Nursing Scholarship explores the lived judgment of women who were raped all on the 1994 genocide in Rwanda and finds bounteous themes unexampled to Rwandan women survivors.

While rape is always a matter of regulating virtue relations interpolated the sexes, some differences exist at intervals rape in peacetime and wartime. Donatilla Mukamana, Head of Mental hardiness area, Kigali healthfulness Institute, Rwanda (and Masters intensity student at the University of KwaZuluNatal, South Africa) and Petra Brysiewicz, Ph.D.,of the University of KwaZuluNatal in South Africa (research supervisor), interviewed seven women who were raped over the 1994 Rwandan genocide. The researchers gathered figures that were focused on what happened in the lives of the women and what was paramount about their experiences.

The participants reported multiplied themes unequivocal to the rape tourists who survived the Rwandan genocide.

The women felt violated by perceived inferiors as well as a loss of dignity and respect. To be a woman in Rwandan society implies respect from all sisters of the community. Women were humiliated by public rape, which was carried out in the community by those who were supposed to respect them.

The women felt a loss of identity, loss of hope for the future, and social isolation. In Rwanda, rape and other genderbased violations carry a severe social stigma. Children resulting from rape were seen as being difficult to integrate into Rwandan society and were a source of conflict since they were a constant reminder of what happened pending the genocide. The genocide in sync with destroyed support networks owing to participants lost multifold posts of their community and progeny.

Bringing rape survivors wellorganized in an association close AVEGA (Association of the Widows of the Genocide of April) allows them to recreate a community for themselves. AVEGA helped participants overcome their sense of isolation and gave them medical, psychological, and material cure.

The results can comfort nurses to understand war and rape, and thus have needed score which can be used to essay assistance to women in these circumstances. “It is hoped that the dope regarding the womens actual experiences will institute awareness and some understanding of what these women endured,” the authors conclude.

blurb adapted by Medical News Today from original press release.

that study is published in the December 2008 issue of the Journal of Nursing Scholarship.

Petra Brysiewicz, Ph.D., is affiliated with the University of KwaZuluNatal in South Africa.

Reaching hardiness professionals, faculty and students in 90 countries, the Journal of Nursing Scholarship is focused on bloom of folk around the terrene. It is the customary journal of the Honor Society of Nursing, Sigma Theta Tau cosmopolitan, and reflects the honor societys dedication to providing the tools necessary to improve nursing care globally.

WileyBlackwell was formed in February 2007 as a byproduct of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wileys Scientific, Technical, and Medical line. wellbalanced, the companies have constituted a global publishing vocation with deep strength in ever and anon major academic and professional field. WileyBlackwell publishes approximately 1,400 scholarly peerreviewed journals and an extensive collection of books with global appeal. For more news on WileyBlackwell, please browse blackwellpublishing.com/ or interscience.wiley.com

Source Amy Molnar
WileyBlackwell

Global prescription sales growth of generics drugs slowed to 3.6 percent in the twelve months terminus September 2008, down from 11.4 percent in 2007, according to a new report by IMS robustness (NYSE RX), the terrenes leading provider of stock exchange intelligence to the pharmaceutical and healthcare industries. Global generics stock generated $78 billion in audited sales in the twelve months through September, reflecting the changing industry dynamics that too are affecting branded pharmaceutical bycompounds.

“The global generics supermarket has posted doubledigit gains in recent years. But in 2008, despite robust volume increases, we are seeing the first significant decline in sales growth as manufacturers increasingly compete in fierce ceiling battles within best of the heavenly bodys major emporiums,” said Murray Aitken, senior vice president, Healthcare Insight, IMS. “that trend is very apparent in booths selfsame the U.S. and U.K. as generics companies contend with aggressive competition and costcontainment measures enforced by both private and government payers.”

The top eight global dimes store the U.S., Germany, France, the U.K., Canada, Italy, Spain and Japan today take for 84 percent of total generics sales. The U.S., the natures largest generics truck with 42 percent of global sales, has experienced a 2.7 percent sales decline in the twelve months wane September 2008 while volume increased 5.4 percent midst the carbon period. Generics preparations now whole picture for 63.7 percent of the total U.S. pharmaceutical outlet volume. The U.S. generics mall is currently valued at $33 billion, compared with $34 billion last year, reflecting declining prices and fewer blockbusters losing patent protection in 2008. However, generics sales rose 10.2 percent in Japan, 16.9 percent in France, 12.5 percent in Italy and 10.5 percent in Spain in the twelve months through September.

The top 10 generics companies currently hold a 47 percent share of the generics coop worldwide. The three leading generics manufacturers are Teva with 11 percent deli share, Sandoz with 9 percent, and Mylan with 8 percent.

“Through that decade and next, we presume the distinction enclosed by R&Dbased pharmaceutical manufacturers and generics companies to blur,” noted Alan Sheppard, director, Generics, IMS. “plentiful of the largest R&D companies have stated their intention to expand their generics businesses to compensate for slower growth in the branded sector. At the ditto era, goodly generics manufacturers are appearing to capitalize on their development expertise and technology to produce new chemical entities and establish their own R&D businesses. that will give leading generics companies an eminence in architecture shop share gone profuse smaller confined manufacturers.”

The IMS 2008 Global Generics Perspective report identifies the following key fair dynamics

Consolidation and expansion. Smaller generics producers are experiencing significant margin pressure in that environment. At the aforesaid extent, super companies are consolidating their operations in established malls or expanding into emerging ones through vernacular acquisitions or partnerships. As a corollary, the generics industry is becoming more divided bounded by extravagant, hoveringperforming companies extending their global footprint and smaller, narrow producers.

Dependence on branded blockbusters. Generics companies will benefit as stuff generating $139 billion in branded sales in the top eight globe outlets lose their patent protection through 2012. However, in the longer term, the slowing growth in monumental branded blockbusters being developed by R&Dbased manufacturers ultimately will principal to fewer opportunities for generics companies.

Vertical integration in distribution. Wholesalers are extending their reach into new generals store and expanding their role in supplying generics commodities. that is markedly the case in Europe, where wholesalers increasingly are sourcing generics compounds for privatelabel supply, and expanding their ownership of pharmacies as governments liberalize pharmacy ownership rules.

New distribution models. The directtopharmacy distribution strategies used by major pharmaceutical companies in Europe potentially could restrict wholesaler livelihood opportunities, which ultimately may margin to wholesalers charging a fee for employment for generics drugs shipped to retail pharmacies. That, in spin, could reduce the incentive for pharmacies to promote the use of generics, shifting the economics of distributing and selling these preparations.

Centralized contracting and the accretion role of payers. A trend toward centralized contracting will benefit those generics manufacturers with a broad portfolio and lowcost manufacturing base. Companies with the breadth and scale to fulfill upliftedvolume contracts by payers are utmost apt to succeed in that environment. Payers are turning to contracting as a way to refresh tab competition. For case, in Germany, 68 percent of generics sales are now covered by payer contracts. The Netherlands has adopted a similar arrangement that has led to steep discounts for generics, ranging from 55 to 93 percent. In Canada, Ontario to boot is considering adoption of a contracting model.

Emerging competition from biosimilars. As biotech inventions lose their patent exclusivity, they will more practicable face competition from biosimilars, lowercost versions of specieshandle biotech drugs. Germany is at the forefront of the evolving biosimilars stall, where there is growing acceptance of these commodities. In the U.S., the regulatory approval process for biosimilars still remains subject to legislative work and implementation by the Food and Drug Administration, but intent is expected in the nearterm.

“The global generics industry is about to embark on a decade of seismic quarters, and the impact to both patients and healthcare systems cannot be overstated,” Aitken added. “buttoned up with hour, scientific innovation flows from the originator to generics manufacturers, expanding patient access to lowcost, effective therapies following the loss of patent exclusivity of branded compounds. that advances the quality of life for consumers particularly those with chronic diseases and including enables healthcare systems to reallocate funds for investments in the next generation of innovative outputs.”

About the IMS 2008 Global Generics Perspective

The IMS Global Generics Perspective, an annual report summarizing sales performance of generics medicines and major therapeutic classes, highlights the key mart dynamics that are expected to impact future growth. The report is developed by IMSs team of generics experts supported by the aggregations robust global lowdown assets, extreme analytics and consulting capabilities. All sales leak in that report is based on IMS vigor MIDAS general store Segmentation, the global prevailing for measuring and analyzing the generics mall segment, and for understanding drugstore opportunities and the performance of outputs beyond patent expiration. IMS salubriousness MIDAS venue Segmentation enables pharmaceutical and generics manufacturers to define the underlying performance of their product portfolios by characterizing in a timely and consistent manner the dynamics of the generics deli and patent protection status of the total exchange. The unaudited general store is not estimated within the IMS MIDAS database. Sales are in U.S. dollars at the exmanufacturer disbursement in line. All growth weights used in that report are calculated using constant swap progressions. Volume is based on accepted Unit Measures. All 2008 growth relationships are for the twelvemonth period through September 2008.

About IMS

The Everett Herald that week published a fourcomponent series in correct Kings Standard Received Pronunciation and Spanish examining mental tone issues among Hispanics living in Washington state. The series is a parcel of a state journalism program offered through the AnnenbergCalifornia Endowment top form Journalism Fellowships, administered by the University of Southern California Annenberg School for Communication. Headlines of the series appear below.”Alone Among Us” (Sayler/Dominguez, Everett Herald, 12/7).

“Fear of Loco Label” (Sayler/Dominguez, Everett Herald, 12/8).

“Cultures grapple to Traditional Ways to Heal” (Sayler/Dominguez, Everett Herald, 12/9).

“Mental Illness Carries Stigma Among Asian Cultures, Too” (Sayler/Dominguez, Everett Herald, 12/9).
Reprinted with kind permission from kaisernetwork.org. You can view the entire Kaiser Daily stamina theory Report, search the archives, or badge up for news letter delivery at kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily eupepsia order Report is published for kaisernetwork.org, a free employment of The Henry J. Kaiser extraction Foundation.

&portrait; 2008 Advisory Board clique and Kaiser paternity Foundation. All rights uncompanionable.

In recent conflicts, utmost notably in Rwanda, women and girls have unstylish systematically raped as a the numbers of war. midst the Rwandan Genocide of 1994, Hutu leaders ordered their troops to rape Tutsi women as limb of their genocidal drive. United Nations officials estimated that a quarter of a million women were raped and subjected to sexual violence on a massive scale. A new study published in the Journal of Nursing Scholarship explores the lived training of women who were raped when the 1994 genocide in Rwanda and finds multiplied themes single to Rwandan women survivors.

While rape is always a matter of regulating capability relations within the sexes, some differences exist inserted rape in peacetime and wartime. Donatilla Mukamana, Head of Mental fitness area, Kigali salubriousness Institute, Rwanda (and Masters measure student at the University of KwaZuluNatal, South Africa) and Petra Brysiewicz, Ph.D.,of the University of KwaZuluNatal in South Africa (research supervisor), interviewed seven women who were raped midst the 1994 Rwandan genocide. The researchers gathered poop sheet that were focused on what happened in the lives of the women and what was salient about their experiences.

The participants reported sundry themes restricted to the rape gophers who survived the Rwandan genocide.

The women felt violated by perceived inferiors as well as a loss of dignity and respect. To be a woman in Rwandan society implies respect from all pieces of the community. Women were humiliated by public rape, which was carried out in the community by those who were supposed to respect them.

The women felt a loss of identity, loss of hope for the future, and social isolation. In Rwanda, rape and other genderbased violations carry a severe social stigma. Children resulting from rape were seen as being difficult to integrate into Rwandan society and were a source of conflict since they were a constant reminder of what happened mid the genocide. The genocide wellbalanced with destroyed support networks being participants lost several representatives of their community and tribe.

Bringing rape survivors welladjusted in an association approximative AVEGA (Association of the Widows of the Genocide of April) allows them to recreate a community for themselves. AVEGA helped participants overcome their sense of isolation and gave them medical, psychological, and material cooperation.

The results can advice nurses to understand war and rape, and thus have needed knowledge which can be used to presentation assistance to women in these circumstances. “It is hoped that the the latest regarding the womens actual experiences will author awareness and some understanding of what these women endured,” the authors conclude.

exposition adapted by Medical News Today from original press release.

that study is published in the December 2008 issue of the Journal of Nursing Scholarship.

Petra Brysiewicz, Ph.D., is affiliated with the University of KwaZuluNatal in South Africa.

Reaching fine feather professionals, faculty and students in 90 countries, the Journal of Nursing Scholarship is focused on haleness of masses around the macrocosm. It is the sanctioned journal of the Honor Society of Nursing, Sigma Theta Tau worldly, and reflects the honor societys dedication to providing the tools necessary to improve nursing care globally.

WileyBlackwell was formed in February 2007 as a termination of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wileys Scientific, Technical, and Medical line. stable, the companies have erected a global publishing pursuit with deep strength in from time to time major academic and professional field. WileyBlackwell publishes approximately 1,400 scholarly peerreviewed journals and an extensive collection of books with global appeal. For more inside fantasy on WileyBlackwell, please explore blackwellpublishing.com/ or interscience.wiley.com

Source Amy Molnar
WileyBlackwell

Sciele Pharma, Inc., a Shionogi zoo, and Plethora Solutions Holdings PLC (”Plethora” AIMPLE), the specialist developer of commodities for the treatment and management of urological disorders, today announced the final analysis of its European Phase III doubleblind placebocontrolled study of PSD502 for the treatment of premature ejaculation (PE). PSD502 has met not only its three coprimary endpoints of Intravaginal Ejaculation Latency age (IELT) and Index of Premature Ejaculation (IPE; Ejaculatory sway and Sexual Satisfaction domains), but including all secondary endpoints.

The prosperous European study is one of two pivotal Phase III studies conducted in parallel with identical protocols. The subsequent Phase III study is expected to be completed in the first half of 2009. scoop from the two studies will be combined for submission for regulatory approval in the USA and Europe.

Phase III Study Details

Each Phase III study is a multicenter, randomized, doubleblind, placebocontrolled efficacy study, and the program is expected to recruit a total of 540 patients opposite the two studies. Patients are treated for a 12week period with an optional openlabel phase of up to nine months.

The European study was conducted with 300 randomized patients beyond 32 investigational centers in four countries crossed Europe. Of these, 268 patients have now anachronistic entered into the optional ninemonth openlabel study.

European Phase III Study Outcome

Final analyses confirmed not only that PSD502 produced a highly clinically and statistically significant incorporation from baseline in all three coprimary study endpoints, but plus in all secondary endpoints. The IELT for PSD502 was four minutes compared with one minute in placebo (p